Tag
The DIABIL-2 trial evaluated low-dose IL-2 therapy for preserving β-cell function in new-onset type 1 diabetes. Despite marked Treg expansion and good safety, IL-2 did not significantly preserve insulin secretion compared to placebo.
A phase 1 trial demonstrates the safety and promising efficacy of expanded minor histocompatibility antigen-specific donor regulatory T cells as a novel prophylactic approach to reduce graft-versus-host disease and improve survival post-all
This phase 1 trial demonstrates that expanded minor histocompatibility antigen-specific donor regulatory T cells, combined with sirolimus prophylaxis, are safe and show promise in preventing acute and chronic GVHD post-allogeneic HCT with d
Single-cell profiling of colorectal cancer lymph nodes revealed an SPP1–CD44–NF-κB1 pathway that promotes CD137+ regulatory T-cell maturation and may be therapeutically targetable.
This review explores the discovery of a two-phase specialization process where CCR8+ regulatory T cells, recruited via the macrophage-derived CCL1 axis, mitigate inflammation and promote cardiac repair following myocardial infarction.
A Phase 1 trial published in NEJM Evidence demonstrates that allogeneic, umbilical cord-derived regulatory T cells are safe and potentially effective in slowing the progression of ALS, providing a scalable, off-the-shelf alternative to trad
The MIROCALS trial evaluated low-dose IL-2 combined with riluzole in ALS, showing safety and immunomodulatory effects, with adjusted analyses suggesting survival benefit in patients with low CSF-pNFH levels, underscoring the role of biomark
A single-center perspective-controlled trial found subcutaneous low-dose IL-2 plus corticosteroids achieved faster disease control in moderate-to-severe bullous pemphigoid and reduced total steroid exposure without serious infections, suppo
A phase 2a randomized trial found low‑dose IL‑2 given every 4 weeks was safe, expanded regulatory T cells, altered peripheral inflammatory mediators, increased CSF Aβ42, stabilized NfL, and trended toward slower cognitive decline in mild–mo
The 2025 Nobel Prize honors the groundbreaking discovery of regulatory T cells (Tregs), key immune modulators that maintain tolerance and prevent autoimmunity, inspiring new therapies for autoimmune disease, transplantation, and cancer.
The 2025 Nobel Prize in Physiology or Medicine honors groundbreaking work on regulatory T cells, revealing how the immune system avoids self-attack while combating threats, paving the way for novel therapies in autoimmune and transplant med
